CG
Publications
184
Views
82 894
Downloads
20 266
Supervised works
11
Items per page
1 - 184 of 184
Title Published in Access level OA Policy Year Views Downloads
Alerte au feu : des nanopompiers pour combattre les flammes de la polyarthrite rhumatoïdeRevue médicale suisse
accessLevelRestricted
2024 66 4
Anti-apolipoprotein A-1 IgG, incident cardiovascular events, and lipid paradox in rheumatoid arthritisFrontiers in cardiovascular medicine
accessLevelPublic
2024 44 12
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studiesJoint bone spine
accessLevelPublic
2024 20 6
IL-18 Binding Protein–Producing Cells Attenuate Anemia in Murine Macrophage Activation SyndromeThe Journal of immunology
accessLevelPublic
2023 80 49
Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseasesFrontiers in immunology
accessLevelPublic
2023 62 24
Reporting and Representativeness of Race, Ethnicity, and Socioeconomic Status in Systemic Sclerosis Randomized Trials: An Observational StudyArthritis care & research
accessLevelPublic
2023 15 6
Special Issue “IL-1 family cytokines in host defense, inflammation and cancer”Cytokine
accessLevelPublic
2022 141 71
Long-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controlsVaccine
accessLevelRestricted
2022 22 0
Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction ModelingArthritis & rheumatology
accessLevelPublic
2022 52 21
Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the jointsCytokine
accessLevelPublic
2022 121 77
Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA on the severity of rheumatoid arthritisRheumatology
accessLevelPublic
2021 305 287
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesRheumatology
accessLevelRestricted
2021 183 0
Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes using disease-related blood biomarkersArthritis and Rheumatology
accessLevelPublic
2021 119 210
Intracellular IL-1 receptor antagonist isoform 1 released from keratinocytes upon cell death acts as an inhibitor for the alarmin IL-1αJournal of Immunology
accessLevelRestricted
2020 289 2
Response to: 'When binary and continuous responses disagree' by Dr OuyangAnnals of the Rheumatic Diseases
accessLevelRestricted
2020 273 2
Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational toolsClinical and Experimental Rheumatology
accessLevelPublic
2020 200 59
Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritisArthritis Research and Therapy
accessLevelPublic
2020 352 87
IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitisLife Science Alliance
accessLevelPublic
2020 134 354
Individual therapeutic DAS28-d crit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studiesRheumatology International
accessLevelPublic
2020 161 38
Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva CocktailClinical Pharmacology and Therapeutics
accessLevelPublic
2020 256 290
Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbiditiesRMD Open
accessLevelPublic
2020 91 31
IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndromeRheumatology
accessLevelRestricted
2020 223 0
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trialThe Lancet
accessLevelRestricted
2020 194 0
The role of the IL-1 system in pregnancy and the use of IL-1 system markers to identify women at risk for pregnancy complications†Biology of Reproduction
accessLevelRestricted
2020 92 0
IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndromeRheumatology
accessLevelRestricted
2020 266 1
Production of IL-18 Binding Protein by Radiosensitive and Radioresistant Cells in CpG-Induced Macrophage Activation SyndromeJournal of Immunology
accessLevelRestricted
2020 221 1
Randomized clinical trials in ANCA-associated vasculitis: a systematic analysis of the WHO - International Clinical Trials Registry PlatformOrphanet Journal of Rare Diseases
accessLevelPublic
2020 107 80
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomesArthritis Research and Therapy
accessLevelPublic
2020 106 51
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in SwitzerlandRMD Open
accessLevelPublic
2020 129 55
Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the diseaseRheumatology
accessLevelRestricted
2020 249 8
Travel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to controls: A multi-centre, observational studyTravel Medicine and Infectious Disease
accessLevelRestricted
2020 109 0
Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumabAdvances in Rheumatology
accessLevelPublic
2019 228 108
Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolutionRheumatology
accessLevelRestricted
2019 300 0
Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort studyRheumatology
accessLevelRestricted
2019 252 0
The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritisBritish Journal of Haematology
accessLevelRestricted
2019 196 0
Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohortRheumatology
accessLevelRestricted
2019 226 0
Long-term therapy with anakinra in hidradenitis suppurativa in three patientsInternational Journal of Dermatology
accessLevelRestricted
2019 250 1
Inadequate reporting of concomitant medications in rheumatology randomized controlled trials of pharmacologic interventionsSeminars in Arthritis and Rheumatism
accessLevelRestricted
2019 229 0
Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritisRMD Open
accessLevelPublic
2019 269 70
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritisSeminars in Arthritis and Rheumatism
accessLevelPublic
2019 259 133
Prevotella copri in individuals at risk for rheumatoid arthritisAnnals of the Rheumatic Diseases
2019 353 0
Variable domain N-linked glycosylation and negative surface charge are key features of monoclonal ACPA: Implications for B-cell selectionEuropean Journal of Immunology
accessLevelRestricted
2018 343 0
Biological agents in the management of adult-onset Still's diseaseJoint, Bone, Spine
accessLevelPublic
2018 371 226
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaborationAnnals of the Rheumatic Diseases
accessLevelRestricted
2018 413 1
Inflammasome Adaptor ASC Suppresses Apoptosis of Gastric Cancer Cells by an IL18-Mediated Inflammation-Independent MechanismCancer Research
accessLevelRestricted
2018 348 0
Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registriesRMD Open
accessLevelPublic
2018 273 112
Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in miceBlood
accessLevelRestricted
2018 412 2
Regulation and function of interleukin-36 cytokinesImmunological Reviews
accessLevelRestricted
2018 397 0
Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET studyRMD Open
accessLevelPublic
2018 356 139
β Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs β Cell Proliferation and Insulin SecretionCell Reports
accessLevelPublic
2018 549 233
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndromeBlood
accessLevelRestricted
2018 289 1
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's diseaseAnnals of the Rheumatic Diseases
accessLevelPublic
2018 384 166
Comparison of Serological Biomarkers in Rheumatoid Arthritis and Their Combination to Improve Diagnostic PerformanceFrontiers in Immunology
accessLevelPublic
2018 331 180
Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritisArthritis Care and Research
accessLevelPublic
2018 375 363
Nanocrystal-Polymer Particles: Extended Delivery Carriers for Osteoarthritis TreatmentSmall
accessLevelPublic
2018 573 356
The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritisSwiss Medical Weekly
accessLevelPublic
2017 522 253
Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritisRheumatology
accessLevelRestricted
2017 448 5
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritisClinical Rheumatology
accessLevelRestricted
2017 518 3
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibitionJournal of Allergy and Clinical Immunology
accessLevelRestricted
2017 381 2
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnnals of the Rheumatic Diseases
accessLevelRestricted
2017 386 2
International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosusAutoimmunity Reviews
accessLevelRestricted
2017 338 1
Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trialsRMD Open
accessLevelPublic
2017 344 212
Cardiovascular risk in patients with rheumatoid arthritisSeminars in Immunopathology
accessLevelRestricted
2017 382 0
Rheumatoid arthritis: from basic findings and clinical manifestations to future therapiesSeminars in Immunopathology
accessLevelRestricted
2017 284 0
Granzyme A Contributes to Inflammatory Arthritis in Mice Through Stimulation of OsteoclastogenesisArthritis and Rheumatology
accessLevelRestricted
2017 462 0
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA CollaborationJournal of Rheumatology
accessLevelRestricted
2017 378 1
Salt-inducible kinases (SIK) inhibition reduces RANKL-induced osteoclastogenesisPLOS ONE
accessLevelPublic
2017 410 141
Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotypePloS one
accessLevelPublic
2017 496 204
IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitroAnnals of the Rheumatic Diseases
accessLevelRestricted
2017 376 0
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumabRMD Open
accessLevelPublic
2017 328 167
The role of female hormonal factors in the development of rheumatoid arthritisRheumatology
accessLevelRestricted
2017 398 0
Deficiency in IL-1 Receptor Type 2 Aggravates K/BxN Serum Transfer-Induced Arthritis in Mice but Has No Impact on Systemic Inflammatory ResponsesJournal of Immunology
accessLevelRestricted
2017 701 2
The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial SpondyloarthritisArthritis & rheumatology
accessLevelRestricted
2016 442 0
A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated diseaseArthritis Research and Therapy
accessLevelPublic
2016 1 001 271
Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's diseaseClinical and experimental immunology
accessLevelRestricted
2016 460 2
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritisAnnals of the rheumatic diseases
accessLevelPublic
2016 461 197
Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokinesCytokine
accessLevelRestricted
2016 456 1
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative studyAnnals of the rheumatic diseases
accessLevelRestricted
2016 456 0
Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritisRheumatology
accessLevelRestricted
2016 480 0
IL-1R1-MyD88 axis elicits papain-induced lung inflammationEuropean Journal of Immunology
accessLevelRestricted
2016 434 0
IL-36-Induced Toxicity in Neonatal Mice Involves TNF-α Production by Liver Myeloid CellsJournal of Immunology
accessLevelRestricted
2016 474 2
Elevated serum levels of free interleukin-18 in adult-onset Still's diseaseRheumatology
accessLevelRestricted
2016 481 0
SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotypeJournal of leukocyte biology
accessLevelRestricted
2016 447 1
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaborationArthritis Research and Therapy
accessLevelPublic
2016 419 171
Effect of particle size on the biodistribution of nano- and microparticles following intra-articular injection in miceInternational journal of pharmaceutics
accessLevelRestricted
2016 814 4
The interleukin (IL)-1 cytokine family--Balance between agonists and antagonists in inflammatory diseasesCytokine
accessLevelRestricted
2015 169 0
Limited Contribution of IL-36 versus IL-1 and TNF Pathways in Host Response to Mycobacterial InfectionPloS one
accessLevelPublic
2015 492 197
Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management RegistryRheumatology
accessLevelRestricted
2015 447 0
Atherosclerosis severity is not affected by a deficiency in IL-33/ST2 signalingImmunity, inflammation and disease
accessLevelPublic
2015 1 124 167
The dermatologists' role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to improve collaboration with rheumatologistsDermatology
2015 400 0
Severe Neutrophil-Dominated Inflammation and Enhanced Myelopoiesis in IL-33-Overexpressing CMV/IL33 MiceThe Journal of immunology
accessLevelRestricted
2015 620 2
Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal studyArthritis research & therapy
accessLevelPublic
2015 485 435
Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort StudyInflammatory bowel diseases
accessLevelRestricted
2015 435 0
Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release systemEuropean journal of pharmaceutics and biopharmaceutics
accessLevelRestricted
2015 618 4
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeuticsArthritis research & therapy
accessLevelPublic
2014 500 309
Immune-mediated experimental arthritis in IL-33 deficient miceCytokine
accessLevelRestricted
2014 603 0
Inflammation: IL-36 has proinflammatory effects in skin but not in jointsNature reviews. Rheumatology
accessLevelRestricted
2014 529 0
Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and kneeInternational orthopaedics
accessLevelRestricted
2014 531 0
Joint damage progression in patients with rheumatoid arthritis in clinical remission. Do biologics perform better than synthetic antirheumatic drugs?Journal of rheumatology
accessLevelRestricted
2014 461 0
Traitement de fond de la polyarthrite rhumatoïdeRevue médicale suisse
accessLevelRestricted
2014 231 2
Biological agents in monotherapy for the treatment of rheumatoid arthritisSchweizerische medizinische Wochenschrift
accessLevelRestricted
2014 498 2
In Black Africans with rheumatoid arthritis, ACPA recognize citrullinated fibrinogen and the derived peptides α36-50Cit38,42 and β60-74Cit60,72,74, like in CaucasiansClinical immunology
accessLevelRestricted
2014 566 1
Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumourAnnals of the rheumatic diseases
accessLevelRestricted
2014 581 2
Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in goutArthritis & rheumatology
accessLevelRestricted
2014 640 0
The severity of experimental arthritis is independent of IL-36 receptor signalingArthritis research & therapy
accessLevelPublic
2013 580 216
Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditionsJournal of leukocyte biology
accessLevelPublic
2013 486 463
Reply to Xie et al. about the article "Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis"Joint bone spine
accessLevelRestricted
2013 510 0
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementAnnals of the rheumatic diseases
accessLevelPublic
2013 636 431
Hand osteoarthritis: new insightsJoint bone spine
accessLevelRestricted
2013 542 0
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditionsAnnals of the rheumatic diseases
accessLevelPublic
2013 565 343
Tocilizumab versus adalimumab for rheumatoid arthritis - Authors' replyLancet
accessLevelRestricted
2013 494 0
Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiencyArthritis research & therapy
accessLevelPublic
2013 586 237
Recommendations for the use of ultrasound in rheumatoid arthritis: literature review and SONAR score experienceSchweizerische medizinische Wochenschrift
accessLevelPublic
2013 778 379
Do synovial leptin levels correlate with pain in end stage arthritis?International orthopaedics
accessLevelPublic
2013 615 145
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trialLancet
accessLevelRestricted
2013 570 0
The Activity of CCL18 is Principally Mediated through Interaction with GlycosaminoglycansFrontiers in immunology
accessLevelPublic
2013 534 269
Endogenous IL-1α is a chromatin-associated protein in mouse macrophagesCytokine
accessLevelRestricted
2013 558 1
Coexistence of seropositive rheumatoid arthritis and SAPHO syndromeJoint bone spine
accessLevelRestricted
2013 564 0
Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trialAnnals of the rheumatic diseases
accessLevelRestricted
2012 614 0
Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatmentsArthritis and rheumatism
accessLevelRestricted
2012 516 1
Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonistsAnnals of the rheumatic diseases
accessLevelPublic
2012 498 375
Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritisJoint bone spine
accessLevelPublic
2012 669 622
Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores?Arthritis care & research
accessLevelRestricted
2012 641 0
Mice deficient in hepatocyte-specific IL-1Ra show delayed resolution of concanavalin A-induced hepatitisEuropean Journal of Immunology
accessLevelRestricted
2012 546 3
The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promotersJournal of leukocyte biology
accessLevelPrivate
2012 614 0
Investigation of Caucasian rheumatoid arthritis susceptibility loci in African patients with the same diseaseArthritis research & therapy
accessLevelPublic
2012 630 321
IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cellsBlood
accessLevelPublic
2012 739 824
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaborationAnnals of the rheumatic diseases
accessLevelRestricted
2012 549 1
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid ArthritisAnnals of the rheumatic diseases
accessLevelPublic
2012 641 543
Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patientsAnnals of the rheumatic diseases
accessLevelRestricted
2012 597 0
Articular inflammation is controlled by myeloid cell-derived interleukin 1 receptor antagonist during the acute phase of arthritis in miceAnnals of the rheumatic diseases
accessLevelRestricted
2012 601 0
Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipientsHaematologica
accessLevelPublic
2011 955 555
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registriesAnnals of the rheumatic diseases
accessLevelRestricted
2011 489 0
IL-36R ligands are potent regulators of dendritic and T cellsBlood
accessLevelRestricted
2011 594 0
Spontaneous secretion of interleukin-17 and -22 by human cervical cells in Chlamydia trachomatis infectionMicrobes and infection
accessLevelRestricted
2011 565 0
Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single centerArthritis and rheumatism
accessLevelRestricted
2011 551 0
Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center studyArthritis and rheumatism
accessLevelRestricted
2011 788 8